KBC Group NV Trims Stake in IDEXX Laboratories, Inc. $IDXX

KBC Group NV lessened its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 44.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 172,679 shares of the company’s stock after selling 136,701 shares during the quarter. KBC Group NV’s holdings in IDEXX Laboratories were worth $97,027,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. SHP Wealth Management bought a new position in IDEXX Laboratories during the 4th quarter valued at about $26,000. Virtus Advisers LLC purchased a new stake in IDEXX Laboratories in the 3rd quarter worth about $26,000. Park Place Capital Corp bought a new stake in IDEXX Laboratories in the fourth quarter worth about $29,000. Mowery & Schoenfeld Wealth Management LLC lifted its stake in IDEXX Laboratories by 58.8% in the fourth quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock worth $37,000 after purchasing an additional 20 shares during the last quarter. Finally, Wormser Freres Gestion boosted its position in shares of IDEXX Laboratories by 671.4% during the fourth quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock valued at $37,000 after buying an additional 47 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently commented on IDXX shares. Stifel Nicolaus cut their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. UBS Group dropped their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Citigroup started coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective on the stock. Finally, Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Tuesday, July 14th. Six investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock opened at $567.44 on Monday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. The stock has a market cap of $44.76 billion, a price-to-earnings ratio of 41.78, a price-to-earnings-growth ratio of 3.10 and a beta of 1.55. The firm has a 50-day moving average of $554.49 and a two-hundred day moving average of $599.33. IDEXX Laboratories, Inc. has a 1 year low of $513.02 and a 1 year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same period last year, the company posted $2.91 earnings per share. The company’s quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, research analysts forecast that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.